Searching for the next blockbuster to follow Darzalex, J&J finds a $150M anti-CD38 drug from partner Genmab
Now that J&J and Genmab have thrust Darzalex onto the regulatory orbit for first-line use in multiple myeloma, the partners are lining up a deal for a next-gen follow-on to the leading CD38 drug.
Janssen — J&J’s biotech unit — has its eyes on HexaBody-CD38, a preclinical compound generated on Genmab’s tech platform designed to make drugs more potent via hexamerization.
Genmab is footing the bill on studies in multiple myeloma and diffuse large B-cell lymphoma; once it completes clinical proof of concept, Janssen has the option to license the drug for a $150 million exercise fee. There’s also $125 million worth of milestones in play.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 62,500+ biopharma pros reading Endpoints daily — and it's free.